Search

everythinglearnresearchcommunity

for

Search:↓

TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.

Alopecia areata is an autoimmune disease causing hair loss, treatable with immune-modulating drugs, and linked to genetics.

Calcipotriol works almost as well as clobetasol for mild to moderate alopecia areata with fewer side effects.

People with certain types of alopecia have a slightly higher risk of cancer, especially thyroid, bladder, and prostate cancers.

Alopecia areata patients have higher levels of IL-6 and TNF-α.

The C3H/HeJ mouse model is useful for studying and testing treatments for alopecia areata.

Grateloupia elliptica extract may help prevent hair loss and promote hair growth.

People with common hair loss conditions may have a higher risk of heart disease and related health issues.

Blood tests can help understand the genetic differences in people with alopecia areata, including how severe it is and if it's inherited.

Stem Cell Educator therapy helps regrow hair and improve life quality in alopecia areata patients.

Alopecia areata is an autoimmune condition causing hair loss due to the immune system attacking hair follicles, often influenced by genetics and stress.

Alopecia areata is caused by immune system attacks on hair follicles, often triggered by viral infections.

The conclusion is that understanding the complex relationship between allergies, autoimmunity, and psychological factors is key to treating skin disorders with itching.

People with alopecia areata have fewer IL-10 producing immune cells, which might contribute to the condition.

Blocking interferon-gamma might help treat various autoimmune diseases.

A specific genetic change is linked to mental disorders, intellectual disability, and possibly autoimmune disease in a family.

Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.

Contact immunotherapy can cause vitiligo in patients with autoimmune conditions.

Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.

Stress hormones and autoimmune reactions can cause hair loss.

People with late-stage HIV-1 often experience a specific type of hair loss linked to multiple factors, including nutritional issues and immune responses.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.

MDSC-Exo can treat autoimmune alopecia areata and promote hair regrowth in mice.

CRTH2 antagonists might be useful for treating many conditions because they play a role in immune and inflammation responses.

The document concludes that more research is needed to better understand and treat primary cicatricial alopecias, and suggests a possible reclassification based on molecular pathways.

The document concludes that ongoing research using animal models is crucial for better understanding and treating Alopecia Areata.

Vogt-Koyanagi-Harada disease can develop during interferon therapy for chronic hepatitis C.

New treatments for vitiligo may focus on protecting melanocyte stem cells from stress and targeting specific pathways involved in the condition.

Certain immune cells contribute to severe hair loss in chronic alopecia areata, with Th17 cells possibly having a bigger impact than cytotoxic T cells.

New protein changes may be involved in the immune attack on hair follicles in alopecia areata.